Inherited resistance to activated protein c caused by presence of the FV:Q506 allele as a basis of venous thrombosis

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 301-314

  Dahlbäck, Björn ^a   Zöller, Bengt ^a   Hillarp, Andreas ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Hypercoagulable states; Resistance to activated protein C; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; CONFERENCE PAPER; ETHNIC GROUP; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; VEIN THROMBOSIS;

ADOLESCENT; BLOOD COAGULATION TESTS; CHILD; DISEASE SUSCEPTIBILITY; ENZYME ACTIVATION; FACTOR V; FACTOR V DEFICIENCY; FEMALE; GENOTYPE; HUMANS; MALE; PHENOTYPE; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN C; PROTEIN S DEFICIENCY; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THROMBOPHLEBITIS; THROMBOSIS;

EID: 0029853540     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217311     Document Type: Article

References (101)

1. Hirsh J. Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol 1986; 8: 104B-113B.
2. Malm J, Laurell M. Nilsson IM, Dahlback B. Thromboembolic disease-critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
3. Hcijboer H. Brandjes D, Biiller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516.
4. Dahlbâck B, Carlsson M, Svensson PJ. Familial thrombophilia duc to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
5. Griffin JH. Evatt BL, Wideman C. Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilie patients. Blood 1993; 82: 1989-1993.
6. Koster T, Rosendaal FR, de Ronde F. Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506.
7. Svensson PJ. Dahlbâck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-521.
8. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilie families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071.
9. Halbmayer WM. Haushofcr A, Schôn R. Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51-57.
10. Liu HW, Kwong YL, Bourke C, et al. High incidence of thrombophilia detected in Chinese patients with venous thrombosis. Thromb Haemost 1994; 71: 416-419.
11. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
12. Greengard JS, Sun X. Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1362-1363.
13. Voorbcrg J, Roelse J, Koopman R, et al. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536.
14. Zôller B, Dahlbâck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538.
15. Zôller B, Svensson PJ, He X, Dahlbâck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
16. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
17. Furie B. Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
18. Broze GJ. The tissue factor pathway of coagulation: factor VII. tissue factor, and tissue factor pathway inhibitor. In: Bloom AL, Forbes CD, Thomas DP, Tuddcnhamn EGD. eds. Haemostasis and Thrombosis, 3rd ed. Edinburgh: Churchill Livingstone, 1995: 349-377.
19. Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and trombotic disorders. Blood 1988: 71: 539-555.
20. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 1988; 57: 915-956.
21. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995; 5; 141-148.
22. Dahlback B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77: 1-43.
23. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995; 9: 946-955.
24. Walker FJ. Regulation of activated protein C by a new protein. J Biol Chem 1980; 255: 5521-5524.
25. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994; 269: 18735-18738.
26. Vdradi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. Thromb Hacmost 1995; 73: 730-731.
27. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994:91: 1396-1400.
28. Sun X, Evatt BL, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125.
29. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.
30. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053-4057.
31. Heeb MJ, Kojima Y. Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-3411.
32. Rosing J, Hoekema L, Nicolaes GAF. et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-27858.
33. Nicolaes GAF. Tans G, Thomasscn MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166.
34. Aparicio C. Dahlback B. Molecular mechanisms of activated protein C resistance based on studies using purified FV:Q506. Biochem J 1996; 313: 467-472.
35. Marlar RA. Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990: 16: 299-309.
36. Zoller B, Holm J, Svensson PJ. Dahlback B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with inherited APC-resistance and/or protein S deficiency. Thromb Haemost 1996: 75: 270-274.
37. Simioni P, Scarano L. Gavasso S. et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC-resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-441.
38. Leroy Matheron C. Lèvent M. Pignon J. Mcndonca C, Gouault Hcilmann M. The 1691 G-> A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996; 75: 4-10.
39. Rosendaal FR, Roster T, Vandenbroucke JP. Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C Resistance). Blood 1995; 85: 1504-1508.
40. Takamiya O, Ishida F. Kodaira H, Kitano K. APC-resistance and Mnll in genotype (Gln506) of coagulation factor V are rare in Japanese population. Thromb Haemost 1995; 74: 996.
41. Rees DC. Cox M. Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
42. de Maat MPM, Klufl C, Jespersen J. Gram J. World distribution of factor V Leiden mutation. Lancet 1996; 347: 58.
43. Braun A, Müller B, Rosche A A. Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C. Hum Genet 1996: 97: 263-264.
44. Holm J, Zoller B, Berntorp E, Erhardt L, Dahlback B. Prevalence of factor V gene mutation among myocardial infarction patients and healthy controls higher in Sweden than in other countries. J Intern Med 1996; 239: 221-226.
45. Zoller B, Dahlback B. Resistance to activated protein C caused by a factor V gene mutation. Current Opinion in Hematology 1995; 2: 358-364.
46. Woo KS, Tse LKK, Tse CY, Metreweli C. Vallance Owen J. The prevalence and pattern of pul monary thromboembolism in the Chinese in Hong Kong. Int J Card 1988; 20: 373-380.
47. Thomas WA, Davies JNP, O'Neal RM, Dimakulangan AA. Incidence of myocardial infarction correlated with venous and pulmonary thrombosis and embolism. A geographic study based on autopsies in Uganda, East Africa and St.Louis, USA. Am J Cardiol 1960; 5: 41-47.
48. Ridker PM. Hennekens CH. Lindpaintner K, Stampfcr MJ, Eisenberg PR. Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
49. Liu XY, Nelson D. Grant C, Morthland V, Goodnight SH. Press RD. Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Diagnostic Molecular Pathology 1995; 4: 191-197.
50. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Aiterioscler Thromh Vase Biol 1995; 15: 783-785.
51. Arruda VR. Annichino-Bizzacchi JM, Costa FF, Rcitsma PH. Factor V Leiden (FVQ 506) is common in a brazilian population. Am J Hematol 1995; 49: 242-243.
52. Nordstrom M, Lindblad B. Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
53. Greengard JS. Eichinger S, Griffin JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-> Gin mutation in the gene for factor V. N Engl J Med 1994: 331: 1559-1562.
54. Majerus, PW. Bad blood mutation. Nature 1994: 369: 14-15.
55. Hopmeier P, Krugluger W. Factor V Leiden and thrombophilia. N Engl J Med 1995;332:1381-1382.
56. Simioni P, Scudcllcr A, Girolami A. Factor V Leiden and thrombophilia. N Engl J Med 1995:332:1382.
57. Koeleman BPC. Reitsma PH. Allaart RC. Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-dcficient families. Blood 1994; 84: 1031-1035.
58. Koeleman BPC. van Rumpf D. Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden. An additional risk factor for thrombosis in protein S deficient families? Thromb Hacmost 1995:74: 580-583.
59. Zoller B, Berntsdotter A. Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditär' deficiency of protein S. Blood 1995; 85: 3518-3523.
60. Beufé S, Borg JY, Vasse M, et al. Co-segregation of thrombosis with the factor V Q506 mutation in an extended family with resistance to activated protein C. Br J Haematol 1995; 89: 659-662.
61. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-213.
62. Bokarewa MI, Brcmme K. Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-478.
63. Vandenbroucke JP, Koster T. Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
64. Bloemenkamp KWM. Rosendaal FR. Helmerhorst FM. Biiller HR. Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346; 1593-1596.
65. Bridey F, Wolff M.JP. Morin V, Lefebvre M. de Prost D. Fatal cerebral venous sinus thrombo sis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 1995; 74: 1382.
66. Levoir D, Emmerich J. Alhenc Gelas M, et al. Portal vein thrombosis and factor V Arg 506 to Gin mutation. Thromb Haemost 1995; 73: 550-551.
67. Press RD. Liu XY, Bcamer N, Coull BM. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke 1996; 27: 44-48.
68. Kontula K, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995: 73: 558-560.
69. van Bockxmeer FM. Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Medicine 1995; 1: 185.
70. Emmerich J, Poirier O. Evans A, et al. Myocardial infarction, Arg506 to Gin factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
71. Sarnani N, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of pre mature myocardial infarction. Lancet 1994; 344: 1709-1710.
72. Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet 1995; 345: 795.
73. Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994; 72: 647.
74. Eritsland J, Gjonnes G, Sandset PM, Seljeflot I, Arnesen H. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 1995; 79: 223-226.
75. Biasiutti FD, Merlo C, Furlan M, Sulzer I, Binder BR, Liimmle B. No association of APC-resistance with myocardial infarction. Blood Coagul Fibrinolysis 1995; 6: 456-459.
76. Marz W, Seydewitz H, Winkclmann B, Chen M, Nauck M. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526-527.
77. Ouriel K. Green RM, Deweese JA, Cimino C. Activated protein C resistance: prevalence and implications in peripheral vascular disease. J Vase Surg 1996; 23: 46-52.
78. Holm J, Zoller B. Svcnsson PJ, Berntorp E, Erhardt L, Dahlback B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-953.
79. Beitina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Reistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-453.
80. Engel H, Zwang L, van Vliet HHDM, Michiels JJ, Stibbe J. Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996; 75: 267-269.
81. Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein resistance. Lancet 1994: 344: 1162-1163.
82. Trossaërt M, Conard J. Horellou MH, et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
83. Tosetto A. Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73: 732-733.
84. Cadroy Y, Sic P. Alheñe Gelas M, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995; 73: 734-735.
85. Dahlback B. Resistance to activated protein C, the Arg506 to Gin mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-742.
86. Jaksch M, v Reuss-Krausse K. Schneppenheim R. Hofmann S, Kaufhold P, Gerbitz KD. Activated protein C (APC)-resistance: Screening of the factor V G1691A mutation using SSCP. Ann Hematol 1995; 70 (Suppl): A64.(Abstract)
87. Gandrillc S, Alheñe Gelas M, Aiach M. A rapid screening method for the factor V Arg506->Gln mutation. Blood Coagul Fibrinolysis 1995; 6: 245-248.
88. van de Locht LTF, Kuypers AWHM. Verbruggen BW, Linssen PCM. Nováková IRO. Mensink EJBM. Semi-automated detection of the factor V mutation by allele specific amplification and capillary electrophoresis. Thromb Haemost 1995; 74: 1276.
89. Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost 1995; 74: 874-878.
90. Rai R, Regan L. Hadley E. Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996: 92: 489-490.
91. De Lucia D, De Blasio G. Belli A, et al. High prevalence of activated protein C resistance in patients with systemic sclerosis. Int J Clin Lab Res 1996: 25: 226-227.
92. Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 94-100.
93. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802.
94. Rintelen C, Pabingcr I, Knobl P, Lechner K, Mannhalter Ch. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-232.
95. Lindblad B. Svensson PJ, Dahlback B. Arterial and venous thromboembolism with fatal outcome in a young man with inherited resistance to activated protein C. Lancet 1994; 343: 917.
96. Simioni P, dc Rode H, Prandoni P, Saladini M, Bertina RM. Girolami A. Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 1995; 26: 885-890.
97. Ganesan V, Kelsey H. Cookson J. Osborn A, Kirkham FJ. Activated protein C resistance in childhood stroke. Lancet 1996; 347: 260.
98. Zollcr B. He X, Dahlback B. Homozygous APC-resistance combined with protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995; 73: 743-745.
99. van Boven HH, Reitsma PH, Rosendaal FR, et al. Interaction of factor V Leiden with inherited antithrombin deficiency. Thromb Haemost 1995: 73: 1256.(Abstract)
100. Gandrille S, Greengard JS, Alhenc Gelas M, et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995; 86: 219-224.
101. 506 allele, and venous thrombosis. Ann Hematol 1996; 72: 166-176.